Abstract
Age-associated B cells (ABCs) accumulate with age, as well as in individuals with a range of immunological dyscrasias. These include patients with cancer treated with immune checkpoint blockade and patients with inborn errors of immunity. In this study, we sought to determine whether ABCs found in all these conditions are similar, and whether they enhance or detract from the response to COVID-19 vaccination. We use single cell RNA sequencing to show that ABCs arising from distinct aetiologies have common transcriptional profiles and may be subdivided according to the expression of genes associated with different immune functions, such as the autoimmune regulator (AIRE). Next, we perform detailed longitudinal profiling of the COVID-19 vaccination response in patients and controls. We show that high pre-vaccination ABC frequency correlates with decreased levels of antigen-specific memory B cells, and reduced magnitude and longevity of neutralising capacity against SARS-CoV-2 virus. Potentially contributing to this, ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes. This could contribute to diminished vaccine responses either directly as result of inhibitory signalling or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may therefore serve as a biomarker identifying individuals at risk of a suboptimal response to COVID-19 vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the MRC (grant ref. MC_UU_00025/12), the Medical Research Foundation (MRF-057-0002-RG-THAV-C0798) and The Evelyn Trust (grant number 20/40). NJM was supported by the MRC (CSF ref. MR/P008801/1 to NJM), NHSBT (grant ref. WPA15-02 to NJM) and Addenbrookes Charitable Trust (grant ref. 900239 to NJM). KW has received funding by the Deutsche Forschungsgemeinschaft (WA 1597/6-1 and WA 1597/7-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was conducted in accordance with the principles of Good Clinical Practice and following granted protocols of the National Institute for Health and Care Research (NIHR) Bioresource of England or granted protocols of the Barts and the London Immunology Registry, United Kingdom. Samples were collected with the written informed consent of all study participants under the NIHR BioResource - Research Tissue Bank (NBR-RTB) ethics (REC:17/EE/0025) or under the Barts and the London Immunology Registry (REC: 11/LO/1689), United Kingdom. Clinical data were collected by Clinical Immunology Consultants at Cambridge University Hospital and Barts Health in London, United Kingdom, via the Electronic Healthcare Record (Epic), or direct patient contact. The patients and healthy controls were consented under the East of England Cambridge South National research ethics committee (REC) reference 13/EE/0325 or Barts and the London Immunology Registry (REC: 11/LO/1689), United Kingdom.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos